Is there an advantage of monitoring via exosome-based detection of EGFR mutations during treatment in non-small cell lung cancer patients?

We know that detection of EGFR mutations is very important for individual therapy. Nowadays FFPE samples are commonly using to detect the mutation status. But it has a few handicaps such as, tumor heterogeneity and non-repeatable, need examine statues after each treatment regimen individually NSCLC patients. Therefore, there still develop non-invasive useable over again approach monitoring other genes So, we aim whether exosomes good target status or not. Pyrosequencing was used detect, in exosome some For patients given different chemotherapy regime (n=28), PFS evaluated before treatment. In who were positive treatment, median mutation-positive 101.7 weeks (95% CI: 0.09-3.21), while negative 42.43 0.31- 10.52). Likewise, 52 0.17-2.84), 27.57 0.35-5.58). show tools can be use as semi-invasive method isolation DNAs